GEN Exclusives

More »

GEN News Highlights

More »
Dec 17, 2007

Crucell Inks Research License Agreement with ProFibrix on STAR

  • Crucell entered into a nonexclusive STAR® research license agreement with ProFibrix covering the production of specific forms of human fibrinogen.

    According to Crucell, STAR technology is a production method that is particularly useful for the production of recombinant human antibodies and proteins.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?